Mengping Long is a pathologist in the Department of Pathology at Peking University Cancer Hospital, where she has been serving since August 2019. She earned both her MBBS and MD from Xiangya School of Medicine, Central South University, and a PhD in Molecular Medicine from Hong Kong University of Science and Technology. Dr. Long's research focuses on the epigenetics and genomics of breast cancer, aiming to elucidate the mechanisms underlying clinical and pathological phenotypes and their impact on treatment outcomes. She has published as the first author in prestigious journals like Nucleic Acids Research and has led projects funded by the National Natural Science Foundation of China (NSFC). Her representative works include studies on histone variants and machine learning approaches for breast cancer subtyping, contributing significantly to the understanding of tumor evolution and drug resistance in breast cancer.